Clinical Trial Update: Effect of Sugammadex for Reversal of Rocuronium-induced Neuromuscular Block on Perioperative Management of Awake Craniotomy [Phase 4]

View source ↗

Summary

Phase 4 trial update evaluating sugammadex for reversal of rocuronium-induced neuromuscular block in awake craniotomy management.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Brain Tumors

Drugs mentioned

• Rocuronium (rocuronium bromide)
• Sugammadex (sugammadex)

Snippet

Sponsor: Guangzhou General Hospital of Guangzhou Military Command | Conditions: Brain Tumors | Phase 4 | Status: UNKNOWN